EP Patent

EP1980252A2 — Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders

Assigned to Avanir Pharmaceuticals Inc · Expires 2008-10-15 · 18y expired

What this patent protects

Dextromethorphan in combination with a CYP2D6 inhibitor can be used to treat pseudobulbar affect, emotional lability, neuropathic pain, a neurodegenerative disease, a neurodegenerative condition, a brain injury, chronic pain, intractable coughing, sexual dysfunction, dematitis, o…

USPTO Abstract

Dextromethorphan in combination with a CYP2D6 inhibitor can be used to treat pseudobulbar affect, emotional lability, neuropathic pain, a neurodegenerative disease, a neurodegenerative condition, a brain injury, chronic pain, intractable coughing, sexual dysfunction, dematitis, or tinnitus.

Drugs covered by this patent

dextromethorphan-hydrobromide (DEXTROMETHORPHAN HYDROBROMIDE)

Patent Metadata

Patent number: EP1980252A2
Jurisdiction: EP
Classification: —
Expires: 2008-10-15
Drug substance claim: No
Drug product claim: No
Assignee: Avanir Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.